Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.53 |
| ▸ | CA2 | P00918 | 12/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6541431 | 0.91 | POLB (0.47) | CA1CA2CA9CA12CA7 | |
| Hydrochloric Acid SCHEMBL28201878 | 0.85 | CA1 (0.53) | CA1CA2CA9CA12STS | |
| SCHEMBL13211050 | 0.82 | CA1 (0.51) | CA1CA2CA9CA12GAA | |
| SCHEMBL1094537 | 0.81 | CNR1 (0.57) | GAA | |
| SCHEMBL3783605 | 0.80 | KDM4E (0.62) | CA1CA2CA9CA12CA7 | |
| SCHEMBL6540686 | 0.79 | MTNR1A (0.43) | CA1CA2CA9CA7MEN1 | |
| SCHEMBL4179064 | 0.79 | HPGD (0.57) | CA1CA2CA9CA12MEN1 | |
| SCHEMBL6433557 | 0.79 | KDM4E (0.61) | CA1CA2GAAMEN1KMT2A | |
| SCHEMBL6540877 | 0.78 | CA1 (0.50) | CA1CA2CA9CA12STS | |
| SCHEMBL6540276 | 0.78 | CA1 (0.55) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107879955-B | Synthetic method of glibenclamide | 广州市桐晖药业有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-107635990-A | Derivative, pharmaceutical composition and the application method of new 3 indoles substitution | 辉瑞公司 | 2018-01-26 | — | — | CN | disclosed |
| US-20040138462-A1 | Aminoalcohol derivatives | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
| EP-1389185-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094770-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138462-A1 | Aminoalcohol derivatives | BPHL, FANCD2, HRH2 | CA1 4181/4885CA2 2242/4885CA9 3759/4885 |
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | CA1 2450/4885CA2 696/4885CA9 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.